For example, activation of SLC11A2 in the brain was associated with toxic iron accumulation, autophagy and cell death in mouse models of Parkinson disease [7] whereas pharmacological modulation of SLC11A2 activity can reverse hepatic iron overload in mouse models of hemochromatosis [4]. This evidence concerns the gene SLC11A2 and hemochromatosis type 1.